Hologic, Inc. $HOLX Shares Purchased by Carnegie Investment Counsel

Carnegie Investment Counsel boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 221,528 shares of the medical equipment provider’s stock after purchasing an additional 21,273 shares during the quarter. Carnegie Investment Counsel owned approximately 0.10% of Hologic worth $14,435,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. United Services Automobile Association acquired a new position in Hologic in the first quarter valued at $347,000. Nordea Investment Management AB increased its stake in Hologic by 7.2% in the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock valued at $168,674,000 after purchasing an additional 174,828 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Hologic in the first quarter valued at $641,000. Cambridge Investment Research Advisors Inc. increased its stake in Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock valued at $1,980,000 after purchasing an additional 528 shares during the last quarter. Finally, Strs Ohio acquired a new position in Hologic in the first quarter valued at $12,910,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on HOLX. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Leerink Partners boosted their price target on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday. Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Evercore ISI set a $78.00 price target on Hologic and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Finally, BTIG Research reissued a “neutral” rating on shares of Hologic in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $79.23.

Insider Activity

In other news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The disclosure for this sale can be found here. 1.88% of the stock is owned by corporate insiders.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $73.89 on Friday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The business has a 50-day moving average of $67.53 and a 200-day moving average of $63.85. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company has a market capitalization of $16.43 billion, a price-to-earnings ratio of 30.66, a PEG ratio of 2.54 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business earned $1.06 earnings per share. The company’s revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.